Raymond Harris Archives
Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
Oct. 22, 2015—A team of Vanderbilt University Medical Center scientists are closer to understanding why COX-2 inhibitors — drugs that relieve arthritis pain and inflammation without the gastrointestinal side effects of other painkillers — cause heart problems in some patients. Now
Oct. 30, 2014—Diabetic nephropathy, or kidney disease caused by diabetes, is a major source of morbidity and mortality. In the United States, more than 30 percent of patients receiving either dialytic therapy or renal transplantation have end stage renal disease as a result of diabetic nephropathy.
May. 29, 2014—Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer.
May. 8, 2014—Vanderbilt University Medical Center, committed to providing multiple options to patients who have kidney disease, recently began offering nocturnal in-center hemodialysis, which allows patients to receive treatment at night while they sleep.
Jan. 20, 2012—The Vanderbilt Digestive Disease Research Center celebrates its 10th anniversary this year with a second five-year renewal of its federal research grant.